A Phase II Study Of Preoperative Everolimus In Metastatic Renal Cell Cancer.

Trial Profile

A Phase II Study Of Preoperative Everolimus In Metastatic Renal Cell Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms E-PREDICT
  • Most Recent Events

    • 02 Oct 2012 Accrual to date is 17% according to United Kingdom Clinical Research Network.
    • 19 Jun 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 18 Apr 2012 United Kingdom Clinical Research Network reports accrual date changed from 15% to 17%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top